Galectin-1 suppresses experimental colitis in mice.

Area of Science:

• Immunology
• Gastroenterology

Background:

• Uncontrolled T-cell activation is central to inflammatory bowel diseases (IBD) pathogenesis.
• Galectin-1, an endogenous lectin, regulates immune tolerance.
• Targeting aberrant T-cells offers a potential therapeutic strategy for IBD.

Purpose of the Study:

• To investigate the therapeutic potential of galectin-1 in a mouse model of T-helper cell type 1-mediated experimental colitis.
• To assess galectin-1's effects on T-cell activation, cytokine production, and apoptosis in the context of colitis.

Main Methods:

• Induction of experimental colitis using 2,4,6-trinitrobenzene sulfonic acid (TNBS) in mice.
• Administration of human recombinant galectin-1 (hrGAL-1) prophylactically and therapeutically.
• Analysis of spleen and colon tissues for morphology, cytokine profiles, and apoptosis.

Main Results:

• hrGAL-1 significantly improved clinical and histopathological features of TNBS-induced colitis.
• Treatment reduced hapten-activated T-cells, inflammatory cytokine production (including IFN-gamma), and lamina propria T-cell activation.
• In vivo administration of hrGAL-1 induced apoptosis in colon tissue, and in vitro studies showed selective apoptosis of TNBS-activated T-cells.

Conclusions:

• hrGAL-1 demonstrates significant protective and immunomodulatory effects in experimental colitis.
• These findings suggest galectin-1 holds therapeutic promise for treating inflammatory bowel diseases.